Background: Pulmonary hypertension (PH) frequently co-exists with severe aortic valve stenosis (AS) and PH severity has been shown to predict long-term outcomes after transcatheter aortic valve implantation (TAVI). The impact of PH etiology on clinical outcomes after TAVI is unknown. Methods: Of 606 consecutive patients undergoing TAVI, 433 (71.4%) patients with severe AS and a pre-procedural right heart catheterization were assessed. Patients were dichotomized according to whether PH was present (mean pulmonary artery [PA] pressure !25mmHg) (n¼325) or not (n¼108). PH patients were further dichotomized by left-ventricular end-diastolic pressure (LVEDP) into post-capillary (LVEDP >15 mmHG; n¼269) and pre-capillary groups (LVEDP 15 mmHg; n¼56). Finally, postcapillary PH patients were divided into passive (n¼133) and reactive (n¼136) subgroups according to whether the transpulmonary gradient was normal ( 12mmHg) or elevated (>12mmHg). Primary-endpoint was all-cause mortality at one year. Results: PH was present in 325/433 (75%) patients and was predominantly postcapillary (n¼269/325; 82%). Compared with baseline, PA systolic pressures immediately improved after TAVI in post-capillary reactive (55.3AE14.4 vs 48.4AE15.5 mmHg, p< 0.001), but not pre-capillary (49.0AE12.6 vs 51.6AE14.3, p¼0.36) patients. As compared with no PH, a higher rate of one-year mortality was observed in both pre-capillary (hazard ratio [HR] 2.30, 95% confidence interval [CI] 1.02-5.22, p¼0.046) and reactive (HR 2.63, 95% CI 1.33-5.20, p¼0.006) but not passive PH patients (p¼0.43). Following adjustment, reactive PH remained an independent predictor of one year mortality after TAVI (HR 2.52, p¼0.01). Conclusions: Hemodynamic stratification of PH by etiology predicts acute response to treatment and long-term mortality after TAVI.
Background: Conventional redo aortic valve replacement (AVR) is associated with high mortality and morbidity, particularly in elderly patients. Transcatheter aortic valve implantation (TAVI) is a less invasive and potentially lower-risk therapeutic option. We sought to assess outcome of Valve-in-Valve (ViV) TAVI for failing stentless AVR performed at our institution. Methods: All 22 patients undergoing 22 ViV TAVI for failing stentless AVR performed at our centre were included. Mean age 74AE12 years, logistic EuroScore 38AE10, all NYHA Class III/IV, 41% had chronic kidney disease, 36% had ascending aorta calcification, 32% had patent coronary bypass grafts, 27% had previous PCI, 14% had pulmonary disease (TLCO < 30%), and 14% had previous stroke. Original implant date ranged 1990 to 2006. All patients had severe aortic regurgitation (AR) due to failing homograft (17), Toronto (3), Freestyle (1) , or native re-suspended aortic valve (1) . Mean left ventricular ejection fraction was 57AE19%. Results: ViV TAVI was performed electively in 7, urgently in 13, and emergently in 2 cases. All received a CoreValve (23mm device in 2, 26mm in 13, 29mm in 6, 31mm in 1). Access route was transfemoral (19), subclavian (2), and direct aortic (1) . The device was deployed too high in 1 case and too low in 2, necessitating TAVI-in-TAVI. In 2 cases, the device migrated high prior to full deployment, requiring lower redeployment. In 1 case, the device embolized into ascending aorta and required surgical removal. 30-day mortality was 0%. Based on VARC-II definitions, rate of myocardial infarction, tamponade, stroke, bleeding, acute kidney injury, and major vascular complications were all 0%. New pacemaker implantation occurred in 14%. Paravalvular AR was absent in 4, mild in 15, mild-moderate in 3. Average length of hospital stay was 9AE6 days, and all patients were discharged home. At long-term (1-55 month) follow-up, 19 patients remained alive (3 deaths; 65 days, 7 months, 9 months). Conclusions: ViV TAVI may be performed in high-risk patients with failing stentless AVR. Lack of fluroscopic markers increases risk of valve migration and embolization. Despite this, 30-day mortality was 0%, with low morbidity, and resolution of AR.
TCT-738
Comparison of vascular and access site complications after transfemoral aortic valve implantation between the CoreValve-Revalving-system and the Edwards Sapien XT valve using serial ultra-sound studies Zentralklinikum Augsburg, Augsburg, Germany, 5 Eberhard-Karls University of Tuebingen, Tuebingen, Germany Background: Transfemoral aortic valve implantation (TAVI) requires large bore catheters. Access site and vascular complications, therefore are of concern. Beside major vascular complications, post-TAVI pseudoaneurysm formation (PAF) is a frequent minor vascular complication. The aim of the study was to compare the incidence of post-TAVI PAF between the CoreValve (CV) using the St.Jude 18-Fsheath and the Edwards Sapien XT valve (ESV) using the 16-20 F Esheath. Methods: Between April 2010 and December 2013, 448 pts (age 81.2 AE 0.4 years) with high surgical risk (Euroscore 24.3 AE 0.8%) underwent successfully TAVI in local anesthesia using either the CV (23,26,29,31mm) or the ESV (23, 26, 29mm). Closure of the access site was perfomed in all pts by using the ProStar XL 10 suture device. All TAVI pts (357 CV and 91 ESV) were examined serially the first 5 days (day 1-3 and 5 post-TAVI) after the procedure by ultrasound (US) for clinically silent vascular complications. In case of PAF, ultrasound-guided manual compression was done followed by compression bandage for another 24 h. Results: In 26 pts (5.6%) we observed major vascular complication after TAVI (19 [5.3 %] after CV and 7 [7.7%] after ESV, p¼0.261). Seven of these 26 pts (26.9%) had to be treated surgically. In 78 pts (17.4%) we observed post-TAVI PAF, which occurred significantly more frequently after implantation of the ESV than after implantation of the CV (19/91 [33.0%] versus 59/357 [16.6%], p¼0.01). However in total only 5 /78 (6.4 %) patients with PAFs had to be treated surgically , the others were treated either by ultrasound guided manual compression or conservatively if smaller than 1 cm. Conclusions: Clinically silent PAF detected by routine US is a frequent post-TAVI minor vascular complication which is more likely to occur after ESV using the Esheath than after CV. Although US-guided compression is highly effective, further miniaturisation of TAVI devices and modification of the Esheath design might help to eliminate post-TAVI PAF.
TCT-739
Improved One Year All Cause Mortality following Transcatheter Aortic Valve Implantation (TAVI) Beyond The Learning Curve Experience: Insights From Glenfield-Leicester UK TAVI Registry Results: Mean age was 82(SD:6 yrs) & 50% were male.Median Euroscore was 17(IQR 10-22).Smoking (54%) and diabetes (20%) were the most common cardiac risk factors.Access route of choice was femoral (94%). Medtronic Corevalve was used most commonly (68%).Permanent pacing was required in 18% of patients & 9% had at least one major complication.Event free survival was significantly higher (92% vs. 65%) in the later time periods (GP 2 and 3: n¼128) compared to that in the "learning curve" group (GP1: n¼60), (log rank p¼0.003),(graph 1).There was a 50% reduction in index procedure hospital stay for the latest cohort compared to the first two cohorts (GP1 & 2 median ¼ 8 days, IQR 4-16 days),(GP3:median:4 days,IQR 3-9 days),(p¼0.002). Conclusions: One year all-cause mortality has improved and hospital stay has reduced over three consecutive time periods.The mortality reduction does not relate to patient characteristics and may have been driven by acquired skills and experience of the TAVI team and advances in valve designs
TCT-740
Transfemoral Aortic Valve Implantation of Edwards Sapien XT without Pre-dilatation is feasible Christoph Liebetrau 1 , Won-Keun Kim 1 , Johannes Blumenstein 1 , Joerg Kempfert 2 , Holger Nef 3 , Arnaud Van Linden 1 , Thomas Walther 4 , Helge Moellmann 1 1 Kerckhoff Heart Center, Bad Nauheim, Germany, 2 Kerckhoff Clinic Bad Nauheim, Bad Nauheim, Germany, 3 Justus-Liebig University of Giessen, Giessen, Germany, 4 Kerckhhoff Heart Center, Bad Nauheim, Germany Background: Transcatheter aortic valve implantation (TAVI) has become the standard intervention for elderly patients with aortic stenosis. Implantation of the valve without pre-dilatation might have some advantages by reducing procedural steps and thereby also the complication rate. This has been demonstrated for the antegrade transapical access with the ballon-expandable Edwards SAPIEN XT valve. However, the feasibility of TAVI with a balloon expandable device without predilatation using the retrograde transfemoral route has not been evaluated yet. Methods: Twenty six consecutive patients with stenosis of the native aortic valve undergoing transfemoral TAVI with the Edwards Sapien XT prosthesis were enrolled in this study. Results: The procedure was successfully performed in all 26 patients -irrespective of the aortic valve area and the extent of aortic valve calcification. At baseline mean aortic valve area, mean AV gradient and median LVEF were 0.7 AE 0.2 cm2, 36.0 AE 17.3 mmHg and 55.0% [IQR 35.0 -60.0]; prior to discharge these values changed as follows: 1.7 AE 0.3 (p < 0.001), 9.8 AE 6.1 mmHg (p < 0.001) and 57.5% [IQR 38.7 -60.0] (p ¼ ns). Postdilatation due aortic regurgitation > 2 was required in 3 cases, leading to aortic regurgitation < 2 in all patients. Of note, no periprocedural neurological adverse events occurred. Conclusions: Transfemoral aortic valve implantation without pre-dilatation using the Edwards Sapien XT is feasible and safe.
TCT-741
Risk Background: The Vancouver Program initiated multidisciplinary and multimodality risk stratification to determine patients' suitability for a transfemoral (TF) minimalist peri-procedural approach, and implemented risk-stratified clinical pathways to facilitate discharge and reduce length of stay. Methods: Standardized screening was implemented to conduct multimodality assessments. Following multidisciplinary eligibility decision for TF TAVR by the Heart Team, additional risk stratification was discussed to determine individuals' appropriateness for the peri-procedural "General Anaesthesia and Transesophageal Echocardiography" ("GA/TEE") and "Awake" (e.g., local anaesthesia) protocols, and the planning requirements for standard (post-procedure day 3) and early (post-procedure day 1-2) discharge protocols. Risk-stratified clinical pathways were developed to support the patient cohorts. Results: 144 consecutive patients were accepted for TF TAVR and assigned to riskstratified protocols. The mean age was 82AE7 years, with the proportion of women ranging from 37% to 42%, and mean STS risk scores between 6.3 and 7.1 in the 4 cohorts. The overall in-hospital outcomes included 2.1% mortality, 0% myocardial infarction, 0.7% stroke, 2.1% life threatening bleeding, 0.7% new dialysis, and 4.2% conduction disturbances requiring a new permanent pacemaker. The median length of stay for all patients was 3 days (IQR 2-3), 2 days (IQR 1-3) in the Awake cohort and 2 (IQR 1-2) in the Early Discharge cohort; 95.8% of patients were discharged home. The 30-day all-cause hospital readmission rate was 11.1%, ranging from 7% and 8% in the Awake and Early Discharge cohorts respectively, to 13% in the GA/TEE and Regular Discharge cohorts; no new deaths occurred between discharge and 30 days. Conclusions: Early experience with TAVR risk stratification, individualized procedure planning and tailored clinical pathways supported by multimodality screening and multidisciplinary case selection and care results in excellent outcomes and optimized length of stay.
TCT-742
Prognostic Value Of Renal Function Recovery In Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI)
